Ryoncil (remestemcel-L-rknd) - MEDICAID - VIRGINIA

Ryoncil (remestemcel‑L‑rknd) is covered as an IV therapy for steroid‑refractory acute graft‑versus‑host disease (aGVHD) following allogeneic hematopoietic cell transplantation in pediatric patients aged 2 months to 17 years with Grade B–D (IBMTR) involvement of skin, liver, and/or gastrointestinal tract. Coverage requires documented failure of systemic corticosteroids per defined timelines (progression by day 3 or no improvement by day 7 on ≥2 mg/kg/day methylprednisolone or equivalent), exclusion of other causes of symptoms, adequate renal function (CrCl >30 mL/min/1.73 m2), medical director review, and excludes pregnancy, DMSO or bovine/murine/porcine protein hypersensitivity and adult patients; repeat doses depend on response assessment at ~28 ± 2 days.

"No explicit limitations, exclusions, frequency limits, age restrictions, or prior‑treatment prerequisites are stated in this excerpt."